Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Your Article Summary
See Latest ArticlesCombined androgen blockade with bicalutamide for advanced prostate cancer
Cancer, 06/23/09
Akaza H et al. - In a study to analyze survival data from a trial in 205 pts with stage C/D prostate cancer (PC) comparing combined androgen blockade (CAB) with luteinizing hormone-releasing hormone agonist (LHRH-A) plus bicalutamide 80 mg vs LHRH-A plus bicalutamide-matching placebo (LHRH-A monotherapy), it was shown that CAB with bicalutamide 80 mg offered a significant overall survival (OS) benefit vs LHRH-A monotherapy without reducing tolerability.
Methods- All deaths irrespective of cause and all PC-specific deaths were recorded.
- Data were analyzed using Cox regression analysis and the log-rank test.
- At a median follow-up of 5.2 yrs, a significant OS advantage was observed in favor of CAB over LHRH-A monotherapy.
- The difference in cause-specific survival between the 2 groups was not significant.
- The achievement of a prostate-specific antigen (PSA) nadir concentration 1 ng/mL was a prognostic factor for improved survival.
- More pts attained PSA nadir concentrations 1 ng/mL with CAB vs pts who received LHRH-A monotherapy (81.4% vs 33.7%).
Related Articles
Recent changes in the landscape of combination RAS blockade
Expert Review of Cardiovascular Therapy, 11/18/09
Relevance Score: 68%
Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs with pimavanserin, a 5-hydroxytryptamine2A receptor inverse agonist
Journal of Pharmacology and Experimental Therapeutics, 11/20/09
Relevance Score: 65%
Antagonistic interaction between bicalutamideTM (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells
The Prostate, 11/18/09
Relevance Score: 65%
Increased androgen bioavailability is associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome
Human Reproduction, 11/05/09
Relevance Score: 65%
Androgens and the breast
Breast Cancer Research, 11/04/09
Relevance Score: 65%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Phase I trial with a combination of docetaxel and 153Sm-lexidronam in patients with castration-resistant metastatic prostate cancer
Urologic Oncology: Seminars and Original Investigations, 12/18/09
Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer
Clinical Cancer Research, 12/18/09
Oral Chemotherapy in Hormone-Refractory Prostate Carcinoma Patients Unwilling to Be Admitted to Hospital
Urologia Internationalis, 12/18/09
Today in Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
High DNA Methyltransferase 3B Expression Mediates 5-Aza-Deoxycytidine Hypersensitivity in Testicular Germ Cell Tumors
Cancer Research, 12/18/09
Phase I trial with a combination of docetaxel and 153Sm-lexidronam in patients with castration-resistant metastatic prostate cancer
Urologic Oncology: Seminars and Original Investigations, 12/18/09
Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer
Clinical Cancer Research, 12/18/09
Today in Prostate...keeping you current
Receive free subspecialty "5-minute updates" via email
Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer
Clinical Cancer Research, 12/18/09
Oral Chemotherapy in Hormone-Refractory Prostate Carcinoma Patients Unwilling to Be Admitted to Hospital
Urologia Internationalis, 12/18/09
Patient Perceived Effectiveness of a New Male Sling as Treatment for Post-Prostatectomy Incontinence
The Journal of Urology, 12/18/09
Article Search
Sponsor